Advertisement

Topics

Moderate-to-Severe Plaque Psoriasis - Biotech, Pharma and Life Science Channel

08:17 EDT 27th May 2018 | BioPortfolio

Psoriasis is a chronic, immune disease that affects the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects up to 1.8 million people in the UK,ix approximately 20 percent of whom have moderate-to-severe plaque psoriasis.Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease. The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.

News Articles [75 Associated News Articles listed on BioPortfolio]

Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International Investigative Dermatology Congress

WESTLAKE VILLAGE, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that pre-clinical data from the Company’s topical product candidate SNA-12...

Psoriatic Arthritis - A Pipeline Analysis Report | Technavio

Technavio has announced their latest pipeline analysis report on the psoriatic arthritis market. The report compris

Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)

Novartis International AG / Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*) . Processed and transmitted by Nasdaq C...

Severe Psoriasis Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14022018] Prices from USD $2250

IntroductionDelveInsight's, Severe Psoriasis Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" report provides comprehensive insights about marketed and Phase III products for ...

Psoriasis Epidemiology Forecast to 2027 [Report Updated: 14022018] Prices from USD $3250

DelveInsight's "Psoriasis Epidemiology Forecast, 2027 report provides a comprehensive analysis of the Psoriasis epidemiology, providing the historical and forecasted data for the 7MM during the for...

Cipher Pharmaceuticals Inc CPH Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryCipher Pharmaceuticals Inc Cipher is a pharmaceutical company that develops skin care solutions. The company offers products such as actikerall, a topical solution indicated for the treatment o...

Psoriasis Market Insight, Epidemiology and Market Forecast 2027 [Report Updated: 14022018] Prices from USD $6250

DelveInsight's "Psoriasis Market Insight, Epidemiology and Market Forecast 2027" report provides a detailed analysis of the Psoriasis epidemiology and market outlook for the 7MM.Markets Covered Un...

Groundbreaking Smart Button & Mobile Health App Klikkit Solves Medication Adherence Challenge

The World’s First Digital Smart Button Designed to Remedy Medication Adherence Problem Launches Kickstarter Campaign Klikkit (https://www.justklikkit.com/), the world...

Encore Dermatology Inc. Announces the Launch of IMPOYZTM (clobetasol propionate) Cream, 0.025%, a Newly Formulated High-Potency Topical Corticosteroid

Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 ...

Exicure Announces Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional spherical nucleic acid (SNA™) constructs, today announced results from the ...

Events [0 Results]

None

Companies [22 Associated Companies listed on BioPortfolio]

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion d...

Arrien Pharmaceuticals

Arrien Pharmaceuticals is a targeted therapeutics drug discovery and development company. Arrien applies its proprietary fragment-based FIELDS drug discovery technology to targ...

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The C...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and a...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Akaal Pharma Pty Ltd.

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery and development company focused on the development of novel small molecule drugs for the treatment of inflam...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and p...

Helmedix Pty Ltd

Helmedix is developing new therapies for autoimmune diseases. The company has identified peptides derived from helminthic worms that have immune-modulating properties. These peptides are being explo...

HealOr

Founded in 2002, HealOr is a privately owned, clinical-stage specialty biopharmaceutical company developing a first-in-class pipeline of topical therapeutics to treat a variety of...

Clinical Trials [637 Associated Clinical Trials listed on BioPortfolio]

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).

Analysis of Cytokine Expression Pattern in Systemic Sclerosis

By contrast to other proinflammatory cytokines which are found up-regulated in the skin of patients with psoriasis, atopic dermatitis or systemic sclerosis, IL-34 is the only cytokine that...

Aggressive Weight Loss Program in Chronic Plaque Psoriasis

Chronic plaque psoriasis is frequently associated with obesity and previous studies have shown that a calorie-controlled diet inducing body weight loss improves symptoms and increases the ...

The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis

Psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. Several cytokines have been found to be involved in the complex pathogenesis of this disease. Il- 36 is o...

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation

The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation.

12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN

This is a 12-Week, multicenter, double-blind, controlled, randomized study assessing change in psoriasis severity and level of stress in patients with moderate to severe psoriasis treated ...

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

The purpose of this study is to investigate whether light therapy can help improve plaque psoriasis. This is a study based on a new medical device. The device produces its light from light...

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone d...

Efficacy and Safety of 2 Secukinumab Regimens in 90 kg or Higher Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Demonstrate superiority of secukinumab high dose over standard dose in heavy body weight subjects with moderate to severe plaque psoriasis.

PubMed Articles [317 Associated PubMed Articles listed on BioPortfolio]

Proanthocyanidins: novel treatment for psoriasis that reduces oxidative stress and modulates Th17 and Treg cells.

Psoriasis is a common, chronic, inflammatory skin disease that affects 2%-4% of the global population. Recent studies have shown that increased oxidative stress (OS) and T-cell abnormalities are centr...

Biologics Monitoring: Incongruity between Recommendations and Clinician Monitoring Trends.

Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients.

A traditional Chinese remedy points to a natural skin habitat: Indirubin (indigo naturalis) for psoriasis and the Malassezia metabolome.

We read with extreme interest the evidence for an impressively high, comparable to current systemic therapies, dose related efficacy of indirubin in plaque psoriasis. Lin and co-authors appropriately ...

Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16,545 biologic-naïve patients from the French national health insurance database (SNIIRAM).

Long-term clinical effectiveness of biologics in psoriasis is needed.

Does Lindioil (Indirubin) treatment affect the composition of Malassezia species on psoriatic skin?

We would like to thank Dr. Gaitanis and co-authors for their interest in our study. To date, many studies have investigated the role of the microbiome in chronic skin inflammatory diseases such as pso...

Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.

Tofacitinib is an oral Janus kinase inhibitor. Final safety and efficacy data from an open-label extension study of tofacitinib in psoriasis are reported.

Are photosensitising medications associated with increased risk of important erythemal reactions during UVB phototherapy?

Erythemal episodes during phototherapy can be painful, limit efficacy due to premature discontinuation of treatment and may contribute to chronic cutaneous damage. Many patients receiving phototherapy...

Vascular Involvement in Axial Spondyloarthropathies.

Ankylosing spondylitis (AS) is a chronic inflammatory joint disease that involves the entheses, causing inflammatory pain and functional impairments. Patients may experience extraarticular manifestati...

Chronotherapy of maxacalcitol on skin inflammation induced by topical 12-O-tetradecanoylphorbol-13-acetate in mice.

In general, chronotherapy is desirable for a more effective and/or safe dosage regimen. In this study, a daily rhythm of skin vitamin D receptor (VDR) and chronotherapeutic profiles of maxacalcitol, a...

Syphilis screening before initiation of immunosuppressive and biologic therapy for psoriasis and psoriatic arthritis.

Videos

None available.

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

review and buy Moderate-to-Severe Plaque Psoriasis market research data and corporate reports here

Channels Quicklinks